Skip to content
Screener

Total debt at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$43.33B-12.3%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.98B+29.5%
Gilead Sciences logo
Gilead SciencesGILD
$26.25B+5.2%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$787.64M+259%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$81.05M-8.9%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$404.11M-5.8%

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$979.59M+32.1%
Enterprise value$971.11M+28.5%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $75.33M.

The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026. Open the filing →

Filed
May 11, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216769

FAQ

What is Sana Biotechnology's total debt?
Sana Biotechnology (SANA) reported total debt of $75.33M in Q1 2026.
How has Sana Biotechnology's total debt changed year-over-year?
Sana Biotechnology's total debt decreased by 17.5% year-over-year, from $91.31M to $75.33M.
What is the long-term trend for Sana Biotechnology's total debt?
Over 5 years (2020 to 2025), Sana Biotechnology's total debt has grown at a 1.9% compound annual growth rate (CAGR), from $71.91M to $78.86M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.

Ask your AI about Sana Biotechnology's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude